// App-Quantinova.ai

976 : Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drug (PWID) in the United States (US): a mathematical model using data from the C‐EDGE CO‐STAR Study

Researchers

Presenter

  • Yiling Jiang

Principal Investigators

  • Chizoba Nwankwo

Medical Centers

  • Merck & Co., Inc.

  • Merck Sharpe & Dohme, Hoddesdon, United Kingdom,

  • Merck & Co., Inc., Kenilworth, NJ

Locations

  • United Kingdom

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Liver cancer

  • Hepatitis C

  • Cirrhosis

  • Solid malignancies

  • STAR syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Elbasvir + grazoprevir

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved